There are 2789 resources available
611P - Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
Presenter: Emmanuel Antonarakis
Session: ePoster Display
613P - Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niamh Keegan
Session: ePoster Display
614P - Circulating tumor cell (CTC) morphologic sub-types present prior to treatment in the CARD trial identify therapy resistance
Presenter: J.S. de Bono
Session: ePoster Display
615P - Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Giorgia Gurioli
Session: ePoster Display
616P - Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis
Presenter: Daniel George
Session: ePoster Display
622P - Geographical assessment of efficacy and safety of relugolix: A subgroup analysis from the randomized, phase III HERO study vs leuprolide (LEU) in men with advanced prostate cancer (APC)
Presenter: Bertrand Tombal
Session: ePoster Display
623P - Real-world treatment patterns in metastatic hormone-sensitive prostate cancer (mHSPC) patients in the US, Germany, France, China and Japan
Presenter: Peter Goebell
Session: ePoster Display
624P - Prevalence and clinical impact of PTEN status in patients (pts) with de novo metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Jonathan Thouvenin
Session: ePoster Display